Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Beneficial Ownership Report · SCHEDULE 13G/A

Korro Bio, Inc.

KRRONASDAQEQUITYCurrent

Beneficial Ownership Report

Filed Nov 16, 2026Accepted Nov 16, 2026, 5:46 PM ESTFiling CIK 1738048Accession 0001738048-26-000096
Share

Structured filing — SCHEDULE 13G/A

primary_doc.xml

Open full document ↗

Amendment · This filing reports the amendment as submitted.

Subject company

Company
Korro Bio, Inc.
Company CIK
0001703647
Street
60 First Street, 2nd Floor, Suite 250
City
Cambridge
State / country code
MA
Postal code
02141

Statement details

Amendment number
1
Security class
Common Stock, par value $0.001 per share
Event date
09/30/2026
Rule designation
Rule 13d-1(c)

Reporting person 1

Name
Venrock Healthcare Capital Partners III, L.P.
Citizenship / organization
DE
Reporting person type
PN
Group designation
a
Aggregate amount owned
1,474,162.00
Percent of class
9.9
Sole voting power
0.00
Shared voting power
1,474,162.00
Sole dispositive power
0.00
Shared dispositive power
1,474,162.00

Reporting person 2

Name
VHCP Co-Investment Holdings III, LLC
Citizenship / organization
DE
Reporting person type
OO
Group designation
a
Aggregate amount owned
1,474,162.00
Percent of class
9.9
Sole voting power
0.00
Shared voting power
1,474,162.00
Sole dispositive power
0.00
Shared dispositive power
1,474,162.00

Reporting person 3

Name
Venrock Healthcare Capital Partners EG, L.P.
Citizenship / organization
DE
Reporting person type
PN
Group designation
a
Aggregate amount owned
1,474,162.00
Percent of class
9.9
Sole voting power
0.00
Shared voting power
1,474,162.00
Sole dispositive power
0.00
Shared dispositive power
1,474,162.00

Reporting person 4

Name
VHCP Management III, LLC
Citizenship / organization
DE
Reporting person type
OO
Group designation
a
Aggregate amount owned
1,474,162.00
Percent of class
9.9
Sole voting power
0.00
Shared voting power
1,474,162.00
Sole dispositive power
0.00
Shared dispositive power
1,474,162.00

Reporting person 5

Name
VHCP Management EG, LLC
Citizenship / organization
DE
Reporting person type
OO
Group designation
a
Aggregate amount owned
1,474,162.00
Percent of class
9.9
Sole voting power
0.00
Shared voting power
1,474,162.00
Sole dispositive power
0.00
Shared dispositive power
1,474,162.00

Reporting person 6

Name
Nimish Shah
Citizenship / organization
X1
Reporting person type
IN
Group designation
a
Aggregate amount owned
1,474,162.00
Percent of class
9.9
Sole voting power
0.00
Shared voting power
1,474,162.00
Sole dispositive power
0.00
Shared dispositive power
1,474,162.00

Reporting person 7

Name
Bong Y. Koh
Citizenship / organization
X1
Reporting person type
IN
Group designation
a
Aggregate amount owned
1,474,162.00
Percent of class
9.9
Sole voting power
0.00
Shared voting power
1,474,162.00
Sole dispositive power
0.00
Shared dispositive power
1,474,162.00

Item 1

Issuer

Korro Bio, Inc.

Principal executive office address

60 First Street, 2nd Floor, Suite 250, Cambridge, MA, 02141.

Item 2

Citizenship

All of the entities were organized in Delaware. Shah and Koh are both United States citizens.

Filing person

The names of the persons filing this report (collectively, the "Reporting Persons") are: Venrock Healthcare Capital Partners III, L.P. ("VHCP III") VHCP Co-Investment Holdings III, LLC ("VHCP Co-Investment III") Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG") VHCP Management III, LLC ("VHCP Management III") VHCP Management EG, LLC ("VHCP Management EG") Nimish Shah ("Shah") Bong Koh ("Koh") The Reporting Persons are members of a group for the purposes of this Schedule 13G/A.

Principal business or residence address

New York Office: 7 Bryant Park, 23rd Floor New York, NY 10018 Palo Alto Office: 3340 Hillview Avenue Palo Alto, CA 94304

Item 3

Not applicable indication

Y

Item 4

Percent of class

Due to the Beneficial Ownership Blocker listed in the Pre-Funded Warrants, each Reporting Person's beneficial ownership percentage as of September 30, 2026 is 9.99%. Such percentage is based upon 13,725,646 shares of common stock outstanding as of September 30, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on November 5, 2026, and giving effect to Pre-Funded Warrants, to the extent exercisable within 60 days hereof, as referenced herein. Due to field limitations of the EDGAR filing system, the percentage listed in Row 11 of each Reporting Person's cover page has been rounded down to 9.9%.

Amount beneficially owned

Row 9 of each Reporting Person's cover page to this Schedule 13G/A sets forth the aggregate number of shares of common stock of the Issuer beneficially owned by such Reporting Person as of September 30, 2026 and is incorporated by reference. The Reporting Persons' ownership of the Issuer's securities consists of (i) 198,756 shares of common stock and pre-funded warrants (the "Pre-Funded Warrants") exercisable for up to 426,762 shares of common stock held by VHCP III; (ii) 19,895 shares of common stock and Pre-Funded Warrants exercisable for up to 42,597 shares of common stock held by VHCP Co-Investment III; and (iii) 224,780 shares of common stock and Pre-Funded Warrants exercisable for up to 2,176,406 shares of common stock held by held by VHCP EG. The Pre-Funded Warrants contain a provision (the "Beneficial Ownership Blocker"), which precludes the exercise of the Pre-Funded Warrants to the extent that, following exercise, VHCP III, VHCP Co-Investment III and VHCP EG, together with their affiliates and other attribution parties, would own more than 9.99% of the common stock outstanding of the Issuer. VHCP III, VHCP Co-Investment III and VHCP EG are currently prohibited from exercising the Pre-Funded Warrants to the extent that such exercise would result in beneficial ownership of more than 1,474,162 shares of common stock of the Issuer. VHCP Management III is the general partner of VHCP III and the manager of VHCP Co-Investment III. VHCP Management EG is the general partner of VHCP EG. Messrs. Shah and Koh are the voting members of VHCP Management III and VHCP Management EG.

Sole voting power

Row 5 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of September 30, 2026 and is incorporated by reference.

Shared voting power

Row 6 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of September 30, 2026 and is incorporated by reference.

Sole dispositive power

Row 7 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of September 30, 2026 and is incorporated by reference.

Shared dispositive power

Row 8 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of September 30, 2026 and is incorporated by reference.

Item 5

Not applicable indication

Y

Item 6

Not applicable indication

Y

Item 7

Not applicable indication

Y

Item 8

Not applicable indication

Y

Item 9

Not applicable indication

Y

Item 10

Not applicable indication

N

Certifications

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

Exhibits

Exhibit 24.1 Power of Attorney for Bong Y. Koh (incorporated by reference to Exhibit 24.1 to the Reporting Persons' Schedule 13G filed with the SEC on March 17, 2026). Exhibit 24.2 Power of Attorney for Nimish P. Shah (incorporated by reference to Exhibit 24.2 to the Reporting Persons' Schedule 13G filed with the SEC on March 17, 2026). Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit 99.1 to the Reporting Persons' Schedule 13G filed with the SEC on March 17, 2026).

Signature 1

Reporting person
Venrock Healthcare Capital Partners III, L.P.
Signed
/s/ Sherman G. Souther
Title
By VHCP Management III, LLC, its General Partner, By Sherman G. Souther, Authorized Signatory
Date
11/16/2026

Signature 2

Reporting person
VHCP Co-Investment Holdings III, LLC
Signed
/s/ Sherman G. Souther
Title
By VHCP Management III, LLC, its Manager, By Sherman G. Souther, Authorized Signatory
Date
11/16/2026

Signature 3

Reporting person
Venrock Healthcare Capital Partners EG, L.P.
Signed
/s/ Sherman G. Souther
Title
By VHCP Management EG, LLC, its General Partner, By Sherman G. Souther, Authorized Signatory
Date
11/16/2026

Signature 4

Reporting person
VHCP Management III, LLC
Signed
/s/ Sherman G. Souther
Title
By Sherman G. Souther, Authorized Signatory
Date
11/16/2026

Signature 5

Reporting person
VHCP Management EG, LLC
Signed
/s/ Sherman G. Souther
Title
By Sherman G. Souther, Authorized Signatory
Date
11/16/2026

Signature 6

Reporting person
Nimish Shah
Signed
/s/ Sherman G. Souther
Title
By Sherman G. Souther, Attorney-in-fact
Date
11/16/2026

Signature 7

Reporting person
Bong Y. Koh
Signed
/s/ Sherman G. Souther
Title
By Sherman G. Souther, Attorney-in-fact
Date
11/16/2026

Company context

Korro is a clinical-stage biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases. OPERA provides precise, tissue-directed delivery of RNA-editing oligonucleotides (REOs) that modify the targeted native mRNA transcript to repair or form a de-novo protein with enhanced functionality. The platform combines a suite of capabilities consisting of sophisticated knowledge of transcription biology through ADAR proteins (Adenosine Deaminases Acting on RNA), machine learning optimization of REOs, linker chemistry expertise, along with use of a highly targeted tissue-specific delivery methodology. As such, the OPERA platform has enabled Korro to generate and advance a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process, providing precise yet transient single base edits to produce therapeutic proteins with augmented activity versus its endogenous counterpart. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an REO-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary OPERA platform with precedented delivery modalities, including N-acetylgalactosamine (GalNAc) conjugated for delivery for subcutan

Current securities

Historical securities (1)

Recent company filings

  1. SCHEDULE 13G/A - filed by BALYASNY ASSET MANAGEMENT L.P. regarding Korro Bio, Inc.Nov 16, 2026
  2. 4 filingNov 13, 2026
  3. SCHEDULE 13G - filed by Adage Capital Management, L.P. regarding Korro Bio, Inc.Nov 12, 2026
  4. 10-Q filingNov 5, 2026
  5. Termination of a Material Definitive Agreement · Results of Operations and Financial ConditionNov 5, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.